Additionally, overcoming the technical and biological challenges inherent in effectively activating the cGAS-STING pathway without triggering excessive or detrimental inflammation and maintaining drug stability and activity within the complex and often immunosuppressive tumor microenvironment remains paramount 103, 106. Here, CGAS is linked to neoplasm.